Results 231 to 240 of about 12,421,057 (398)

PD15 The long road to diagnosis: a single-centre study of delays and disease burden in photodermatoses [PDF]

Thomas Morrall, Donna Parkin, Jean Ayer
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Expansion of the quality of care index on breast cancer and its risk factors using the global burden of disease study 2019

, 2022
Sina Azadnajafabad, Sahar Saeedi Moghaddam, Mohammad Keykhaei, Parnian Shobeiri, Negar Rezaei, Erfan Ghasemi, Esmaeil Mohammadi, Naser Ahmadi, Azin Ghamari, Sarvenaz Shahin, Nazila Rezaei, Mahdi Aghili, Ahmad Kaviani, Bagher Larijani, Farshad Farzadfar   +14 more
openalex   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Hereditary factor X deficiency in America survey: impact on quality of life and burden of disease in patients and caregivers

Brian R. Branchford, Kim Clark, Richard H. Stanford, Denise Garner, Shirley P. Huang, Eric Wolford   +5 more
openalex   +1 more source

Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy

BDJ, 2012
I-Min Lee, Eric J. Shiroma, Felipe Lobelo, Pekka Puska, Steven N. Blair, P. Katzmarzyk   +5 more
semanticscholar   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Impact of exposure frequency on disease burden of the common cold - A mathematical modeling perspective. [PDF]

PLoS One
Gerdes S, Rank M, Glauche I, Roeder I.
europepmc   +1 more source

Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019

, 2022
Isabela M Benseñor
openalex   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source